<DOC>
	<DOCNO>NCT00488319</DOCNO>
	<brief_summary>The purpose open-label study evaluate long-term ( 6-month ) safety tolerability extended-release paliperidone , atypical antipsychotic , give flexible dosage adolescent schizophrenia .</brief_summary>
	<brief_title>Open-label Study Flexible-dose Paliperidone ER ( Extended Release ) Treat Adolescent Schizophrenia .</brief_title>
	<detailed_description>This 6-month , open-label study ( patient , investigator , sponsor know study drug dosage take patient ) safety tolerability flexible-dose ( 1.5 12mg per day ) , extended-release ( ER ) paliperidone adolescent diagnosis schizophrenia . Patients complete study R076477PSZ3001 discontinue study lack efficacy complete minimum 21 day study may enter study . Patients may also enter study directly without participate R076477PSZ3001 . This study consist 21-day screen washout phase ( discontinue `` wash '' medication allow study ) , open-label treatment phase 26 week patient take oral paliperidone ER every day , post-treatment phase consist follow-up visit complete 1 week patient receive final dose paliperidone ER . The study , include screen posttreatment phase , last approximately 30 week . Screening washout may conduct patient either inpatient outpatient . Safety assess laboratory measurement ( chemistry , liver function test , hematology , hormone , lipid assessment , prolactin [ blind ] , urinalysis , urine drug screen ) ; body weight , height , waist circumference measurement ; ECGs ; physical examination ( include Tanner stag ) . The Abnormal Involuntary Movement Scale ( AIMS ) , Barnes Akathisia Rating Scale ( BARS ) , Simpson Angus Rating Scale ( SAS ) use assess extrapyramidal symptom ( EPS ) dyskinesia . Adverse event monitor include psychiatric adverse event interest ( i.e. , suicide related phenomenon , homicidal ideation , depress mood , worsen psychosis ) may associate paliperidone ER population . The primary aim study evaluate long-term ( 6-month ) safety tolerability paliperidone ER adolescents schizophrenia . As exploratory secondary aim , study assess effect paliperidone ER long-term symptom schizophrenia measure change Positive Negative Syndrome Scale Schizophrenia ( PANSS ) score , global improvement severity illness measure Clinical Global Impression-Severity ( CGI-S ) scale , benefit psychological , social , school functioning measure Children 's Global Assessment Scale ( CGAS ) , change multiple domain cognitive functioning measure modified Measurements Treatment Research Improve Cognition Schizophrenia ( MATRICS ) assessment battery , effect sleep measure sleep Visual Analog Scale ( VAS ) . Patients begin study 6.0 mg/day oral paliperidone ER . If high dosage need , dosage increase ( increment 3 mg/day frequently every 5 day ) 12 mg/day . If 6.0 mg/day dosage well tolerate , dosage may decrease ( frequently every 5 day ) 3.0 mg/day 1.5 mg/day . Patients dose 6 month .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Meets DSMIV criterion schizophrenia , otherwise physically healthy Weight &gt; =63.9 pound ( 29 kg ) Must danger self others must family support available maintain outpatient Responsible adult must available accompany patient investigational site visit . Meets DSMIV criterion dissociative disorder , bipolar disorder , major depressive disorder , schizoaffective disorder , schizophreniform disorder , autistic disorder , primary substanceinduced psychotic disorder mild , moderate , severe mental retardation History substance dependence ( include alcohol , exclude nicotine caffeine ) accord DSMIV criterion 3 month screen pregnancy ( female ) History presence circumstance may increase risk occurrence torsade de pointes sudden death association use drug prolong QTc interval .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Antipsychotic agent</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>Psychosis .</keyword>
</DOC>